


MitoPlate™ Technology

Analyzing Mitochondria at Higher Resolution

New Probes of Mitochondrial Function

MitoPlates from Biolog provide a powerful new research tool by allowing scientists to run preconfigured sets of 96 mitochondrial function assays in one experiment. Mitochondria can be interrogated and characterized in novel ways, looking at rates of substrate metabolism, sensitivity to drugs and other chemicals, and effects of mutations in mitochondria-related genes.



Substrates or inhibitors permeate the cell membrane and enter mitochondria, stimulating or inhibiting production of NAD(P)H or FADH₂ which is then measured using a tetrazolium redox dye.

Investigate how mitochondria change with:

- Cell differentiation
- Cancer & ageing
- Neurological disorders
- Metabolic disorders
- Immune cell activation
- Bacterial/viral infection
- Inborn genetic defects

Assay Principle



Mitochondrial function is assayed by measuring the rates of electron flow into and through the electron transport chain from metabolic substrates that produce NAD(P)H or FADH₂ such as L-malate, succinate, pyruvate, etc. Each substrate follows a different route, using different transporters to enter the mitochondria and different dehydrogenases to produce NAD(P)H or FADH₂. The electrons travel from the beginning (complex 1 or 2) to the distal portion of the electron transport chain where a tetrazolium redox dye (MC) acts as a terminal electron acceptor that turns purple upon reduction. Additional MitoPlate assays probe the sensitivity of the mitochondria to a set of 22 diverse inhibitors.

MitoPlate S-1 with 30 Substrates:

No Substrate Control	α -D-Glucose	Glycogen	D-Glucose-1-PO ₄
D-Glucose-6-PO ₄	D-Gluconate-6-PO ₄	D,L- α -Glycerol-PO ₄	L-Lactic Acid
Pyruvic Acid	Citric Acid	D,L-Isocitric Acid	cis-Aconitic Acid
α -Keto-Glutaric Acid	Succinic Acid	Fumaric Acid	L-Malic Acid
α -Keto-Butyric Acid	D,L- β - Hydroxy-Butyric Acid	L-Glutamic Acid	L-Glutamine
Ala-Gln	L-Serine	L-Ornithine	Tryptamine
Sparker Malate Control	Acetyl-L-Carnitine	Octanoyl-L-Carnitine	Palmitoyl-D,L-Carnitine
Pyruvic Acid	γ -Amino-Butyric Acid	α -Keto-Isocaproic Acid	L-Leucine

MitoPlate I-1 with 22 Inhibitors:

No Substrate Control	No Inhibitor Control	Meclizine
Complex I Inhibitor Rotenone	Complex I Inhibitor Pyridaben	Berberine
Complex II Inhibitor Malonate	Complex II Inhibitor Carboxin	Alexidine
Complex III Inhibitor Antimycin A	Complex III Inhibitor Myxothiazol	Phenformin
Uncoupler FCCP	Uncoupler 2,4-Dinitrophenol	Diclofenac
Ionophore, K Valinomycin	Calcium / CaCl ₂	Celastrol
Gossypol	Nordihydro-guaiaretic acid	Trifluoperazine
Polymyxin B	Amitriptyline	Papaverine



Simple Assay Procedure:

- STEP 1:** Prepare and pipet assay mixture containing cell permeabilizing buffer and redox dye into appropriate wells.
- STEP 2:** Start the assays by adding 2x cell suspension to all wells.
- STEP 3:** Load the MicroPlate into the OmniLog® for kinetic reading of the rate of purple color formation.

Unique Features and Advantages:

- MitoPlates are preloaded with 96 tests ready for use
- Plates designed to measure effects of substrates and inhibitors on mitochondrial function
- Easy, robust protocols with any cell type – adherent or suspension cells, transformed cell lines or primary cells
- Assays need only 20,000 to 40,000 cells per well
- Novel tetrazolium dye chemistry provides a terminal electron acceptor in easy to read colorimetric assays
- OmniLog instrument provides automated temperature controlled incubation and kinetic reading of multiple plates (50 plates at 15 min, or 16 at 5 min intervals)

Ordering Information:

Catalog #	Description
14104	MitoPlate I-1
14105	MitoPlate S-1
72303	Biolog MAS
74353	Biolog Redox Dye Mix MC
96161	OmniLog PM-M System (NA Plug)
96162	OmniLog PM-M System (Schuko Plug)
96164	OmniLog PM-M System (UK Plug)

Not Included: Saponin permeabilizing solution and substrate solutions for MitoPlate I-1. Please review Instructions for Use prior to ordering.

OmniLog System and Analysis Software

The OmniLog Instrument and associated software allows for real-time recording and kinetic analysis of electron flow rates. The OmniLog can simultaneously incubate and read up to 50 MitoPlates and provides powerful analysis tools to get the most from your experimental data.

New Mitochondrial Function Assay Technology

Lawrence A. Wiater, Kyle O'Hollaren, Xiang-He Lei, and Barry R. Bochner
Biolog, Inc. Hayward, CA, USA


Abstract

We have developed a new mitochondrial function assay technology that measures the rates of metabolism of mitochondrial substrates and the sensitivity of metabolism of these substrates to mitochondrial inhibitors. The technology employs saponin permeabilized cells and a redox dye added to 96-well microplates that contain mitochondrial substrates or inhibitors pre-coated and dried into the wells. The MitoPlate S-1™ has a triplicate repeat of a set of 31 substrates. Mitochondrial function is assayed by measuring the rates of dye reduction from electrons flowing into and through the electron transport chain from substrates whose oxidation produces NADH (e.g., L-malate) or FADH₂ (e.g., succinate). The electrons donated to complex 1 or complex 2 travel to the distal portion of the electron transport chain where a tetrazolium redox dye (MC) acts as a terminal electron acceptor and changes from colorless to a purple formazan upon reduction. All 96 assays in the MitoPlate are run concurrently, and each assay provides different information because each substrate follows a different metabolic route using different transporters to enter the mitochondria, and then different dehydrogenases to produce NADH or FADH₂. The MitoPlate S-1™ can also be used to assess the activity and specificity of substrate transport inhibitors, dehydrogenase inhibitors, or electron transport chain inhibitors. A second assay plate, the MitoPlate I-1™, provides another assessment of mitochondrial function by measuring the sensitivity of mitochondrial electron flow to a set of 22 diverse inhibitors titrated at 4 dilutions. The I-1 plates can be run using any of the NADH or FADH₂ producing substrates, each providing additional information. Using these new assays we show that the mitochondria from different cell types exhibit different functional properties. This new technology will assist efforts to understand how mitochondria change in cell models of human disorders that have a mitochondrial basis.

The Assay Technology

Figure 1 outlines the simple assay protocol. 30 µl of a permeabilizing assay mix containing saponin and Redox Dye MC in isotonic buffer is pipetted into all wells and incubated at 37° C for 1 hour. To start the assay, 30 ul of a cell suspension in isotonic buffer is added to each well. The recommended cell density is 1,000,000 cells/ml resulting in 30,000 cells/well. To record the rates of dye reduction in the wells, the MitoPlate is loaded into the OmniLog, which reads at 5 minute intervals for 2 to 4 hours. For MitoPlate I-1 with 22 mitochondrial inhibitors, the permeabilizing assay mix also contains an NADH or FADH₂ producing substrate such as L-malate or succinate. **Figure 3 and 4** show, respectively, the test layout in the MitoPlate S-1 and the MitoPlate I-1.

Figure 1. The Assay Protocol.



Assays and Results

Figure 2. With this assay technology, mitochondrial function is profiled in a new way by measuring the rates of dye reduction from electrons flowing into and through the electron transport chain from substrates whose oxidation produces NADH or FADH₂.




Figure 3. The MitoPlate S-1 simultaneously assays the metabolic rates of potential NADH or FADH₂ producing substrates.

A1 No Substrate	A2 D-Glucose	A3 Citrovit	A4 D-Glucose-1-PHA	A5 No Substrate	A6 D-Glucose	A7 Citrovit	A8 D-Glucose-1-PHA	A9 No Substrate	A10 D-Glucose	A11 Citrovit	A12 D-Glucose-1-PHA
B1 D-Glucose-1-PHA	B2 D-Glucose-1-PHA	B3 D,L-Glycerol-PHA	B4 L-Lactic Acid	B5 D-Glucose-1-PHA	B6 D-Glucose-1-PHA	B7 D,L-Glycerol-PHA	B8 L-Lactic Acid	B9 D-Glucose-1-PHA	B10 D-Glucose-1-PHA	B11 D,L-Glycerol-PHA	B12 L-Lactic Acid
C1 Pyruvic Acid	C2 Citric Acid	C3 D,L-Succinic Acid	C4 D,L-Succinic Acid	C5 Pyruvic Acid	C6 Citric Acid	C7 D,L-Succinic Acid	C8 D,L-Succinic Acid	C9 Pyruvic Acid	C10 Citric Acid	C11 D,L-Succinic Acid	C12 D,L-Succinic Acid
D1 L-Aspartic Acid	D2 Succinic Acid	D3 Pyruvic Acid	D4 L-Malic Acid	D5 L-Aspartic Acid	D6 Succinic Acid	D7 Pyruvic Acid	D8 L-Malic Acid	D9 L-Aspartic Acid	D10 Succinic Acid	D11 Pyruvic Acid	D12 L-Malic Acid
E1 L-Aspartic Acid	E2 D,L-β-Hydroxybutyric Acid	E3 L-Glutamic Acid	E4 L-Glutamic Acid	E5 L-Aspartic Acid	E6 D,L-β-Hydroxybutyric Acid	E7 L-Glutamic Acid	E8 L-Glutamic Acid	E9 L-Aspartic Acid	E10 D,L-β-Hydroxybutyric Acid	E11 L-Glutamic Acid	E12 L-Glutamic Acid
F1 D-Glc	F2 D-Glc	F3 D-Glc	F4 D-Glc	F5 D-Glc	F6 D-Glc	F7 D-Glc	F8 D-Glc	F9 D-Glc	F10 D-Glc	F11 D-Glc	F12 D-Glc
G1 Malate Acid	G2 Succinate Acid	G3 Succinate Acid	G4 Succinate Acid	G5 Malate Acid	G6 Succinate Acid	G7 Succinate Acid	G8 Succinate Acid	G9 Malate Acid	G10 Succinate Acid	G11 Succinate Acid	G12 Succinate Acid
H1 Pyruvic Acid	H2 L-Aspartic Acid	H3 L-Aspartic Acid	H4 L-Aspartic Acid	H5 Pyruvic Acid	H6 L-Aspartic Acid	H7 L-Aspartic Acid	H8 L-Aspartic Acid	H9 Pyruvic Acid	H10 L-Aspartic Acid	H11 L-Aspartic Acid	H12 L-Aspartic Acid

Figure 4. The MitoPlate I-1 simultaneously assays the sensitivity of NADH or FADH₂ producing pathways to 22 mitochondrial inhibitors.

A1 No inhibitor	A2 No inhibitor	A3 No inhibitor	A4 No inhibitor	A5 No inhibitor	A6 No inhibitor	A7 No inhibitor	A8 No inhibitor	A9 No inhibitor	A10 No inhibitor	A11 No inhibitor	A12 No inhibitor
B1 Complex I inhibitor	B2 Complex I inhibitor	B3 Complex I inhibitor	B4 Complex I inhibitor	B5 Complex I inhibitor	B6 Complex I inhibitor	B7 Complex I inhibitor	B8 Complex I inhibitor	B9 Complex I inhibitor	B10 Complex I inhibitor	B11 Complex I inhibitor	B12 Complex I inhibitor
C1 Complex II inhibitor	C2 Complex II inhibitor	C3 Complex II inhibitor	C4 Complex II inhibitor	C5 Complex II inhibitor	C6 Complex II inhibitor	C7 Complex II inhibitor	C8 Complex II inhibitor	C9 Complex II inhibitor	C10 Complex II inhibitor	C11 Complex II inhibitor	C12 Complex II inhibitor
D1 Complex III inhibitor	D2 Complex III inhibitor	D3 Complex III inhibitor	D4 Complex III inhibitor	D5 Complex III inhibitor	D6 Complex III inhibitor	D7 Complex III inhibitor	D8 Complex III inhibitor	D9 Complex III inhibitor	D10 Complex III inhibitor	D11 Complex III inhibitor	D12 Complex III inhibitor
E1 Rotenone	E2 Rotenone	E3 Rotenone	E4 Rotenone	E5 Rotenone	E6 Rotenone	E7 Rotenone	E8 Rotenone	E9 Rotenone	E10 Rotenone	E11 Rotenone	E12 Rotenone
F1 Malonate	F2 Malonate	F3 Malonate	F4 Malonate	F5 Malonate	F6 Malonate	F7 Malonate	F8 Malonate	F9 Malonate	F10 Malonate	F11 Malonate	F12 Malonate
G1 FCCP	G2 FCCP	G3 FCCP	G4 FCCP	G5 FCCP	G6 FCCP	G7 FCCP	G8 FCCP	G9 FCCP	G10 FCCP	G11 FCCP	G12 FCCP
H1 Valproic Acid	H2 Valproic Acid	H3 Valproic Acid	H4 Valproic Acid	H5 Valproic Acid	H6 Valproic Acid	H7 Valproic Acid	H8 Valproic Acid	H9 Valproic Acid	H10 Valproic Acid	H11 Valproic Acid	H12 Valproic Acid
I1 Carbonyl	I2 Carbonyl	I3 Carbonyl	I4 Carbonyl	I5 Carbonyl	I6 Carbonyl	I7 Carbonyl	I8 Carbonyl	I9 Carbonyl	I10 Carbonyl	I11 Carbonyl	I12 Carbonyl
J1 Polystyrene II	J2 Polystyrene II	J3 Polystyrene II	J4 Polystyrene II	J5 Polystyrene II	J6 Polystyrene II	J7 Polystyrene II	J8 Polystyrene II	J9 Polystyrene II	J10 Polystyrene II	J11 Polystyrene II	J12 Polystyrene II

Figure 5. Colon and liver cells were assayed for substrate metabolism using the MitoPlate S-1. Four major differences were found in their metabolism.






Figure 6. Colon cells were assayed in MitoPlate I-1 with L-malate as the substrate. The cells were sensitive to Complex 1 and 3 inhibitors, but not Complex 2 inhibitors.

Figure 7. Colon cells were assayed in MitoPlate I-1 with succinate as the substrate. The cells were sensitive to Complex 2 and 3 inhibitors, but not Complex 1 inhibitors.



Conclusions

The MitoPlate assay technology enables profiling of mitochondrial function in much greater detail. The MitoPlates have 53 phenotypic assays already dried in the wells, so they can be tested at the same time by simply inoculating with a cell suspension. The assays are colorimetric and can be performed using any kinetic microplate reader. The technology provides a simple and highly sensitive discovery tool for mitochondrial researchers.

BIOLOG


MitoPlate™ S-1 and MitoPlate™ I-1 *for Characterization of Mammalian Cell Mitochondria*

*Assays: Mitochondrial Substrate Metabolism
Sensitivity to Mitochondrial Inhibitors*

PRODUCT DESCRIPTIONS AND INSTRUCTIONS FOR USE

MitoPlate S-1 Cat. #14105

MitoPlate I-1 Cat. #14104



21124 Cabot Blvd.
Hayward, CA 94545
TEL 510-785-2564, FAX 510-782-4639
ORDERS 1-800-284-4949
www.biolog.com

The most current version of this Technical Bulletin can be downloaded from Biolog's website at www.biolog.com. Questions about the use of this product should be directed to Biolog, Inc. Technical Services by E-mail at tech@biolog.com. OmniLog® is a registered trademark of Biolog, Inc. and the OmniLog instrument is covered by U. S. Patent No. 6,271,022, owned by Biolog, Inc.

For Research Use Only

Part# 00P 273, Rev C, October 2020

CONTENTS

I.	Introduction.....	2
	a. Overview	2
	b. Background	2
	c. Uses	2
	d. Advantages.....	2
II.	Product Descriptions.....	4
III.	Protocol Information.....	4
	a. Cell Number Optimization.....	4
	b. Cell Permeabilization Optimization	4
IV.	MitoPlate S-1 Instructions For Use.....	5
V.	MitoPlate I-1 Instructions For Use.....	7
VI.	References.....	9
VII.	Frequently Asked Questions.....	12

I. Introduction

a. Overview

MitoPlates™ from Biolog provide a powerful research tool by allowing scientists to run preconfigured sets of 96 mitochondrial function assays in one experiment. Mitochondria can be interrogated and characterized in novel ways, looking at rates of substrate metabolism, sensitivity to drugs and other chemicals, and effects of mutations in mitochondrial genes.

b. Background

Mitochondria play a primary role in energy production by cells. It is clear that these organelles are dynamic as the quantity and structure of the mitochondria in cells can change. Mitochondria are complex, consisting of over 1,000 proteins, the vast majority of which are coded for by nuclear rather than mitochondrial DNA. In addition to proteins, mitochondria also have specialized membranes and they can interact with each other and with other cellular organelles such as endoplasmic reticuli.

c. Uses

By providing a new high resolution approach to assaying mitochondrial function, MitoPlates allow scientists to investigate how mitochondria change with differentiation, cancer and ageing, neurological disorders, metabolic disorders, immune cell activation, bacterial/viral infection, inborn genetic disorders, or any other change that can be experimentally modeled at the cellular level.

d. Advantages


MitoPlates provide a unique and powerful tool for simultaneously running 96 relevant assays to elucidate changes in mitochondrial properties. Some principal advantages are:

- **Proven Technology:** A sizeable volume of published literature documents the successful use of Biolog's PMM and MitoPlate technology as applied to mammalian cell research. An updated listing can be found in the Bibliography section of the Biolog website at

<http://www.biolog.com/bibliography.php>. The PMM technology is based upon measurement of live cell properties using a bioenergetics detection chemistry. The MitoPlates are an extension of PMM technology, performing similar bioenergetics detection, but on live cells that are instantaneously permeabilized to allow access to the mitochondrial organelles.

- **Simple Protocol:** Add the permeabilizing buffer with dye mix, add the cells, and read the rate of purple color formation. Purification of mitochondria is not required.
- **Fast Results:** For rate measurements, sufficient color forms in as little as two hours. The purple formazan product is soluble and stable and can be measured as soon as it forms.
- **Flexible Format:** The Biolog OmniLog® instrument is recommended for reading the MitoPlates because it can read multiple plates kinetically (up to 16 at 5 minute read intervals) while under temperature-controlled incubation. However, the MitoPlates can also be read with standard microplate readers that allow kinetic reading at OD₅₉₀.
- **Sensitivity:** The MitoPlate assays work with as little as 20,000 cells per well.
- **Broad Applicability:** The MitoPlates can be used with nearly any type of cell line or primary cell. The main requirement is that a uniform cell suspension must be prepared so that each well receives the same amount of cells. For these assays it does not matter if the cells are attached to the well bottom or floating in suspension.
- **High Resolution Analysis:** The Figure below highlights the numerous assay options including measurement of (1) Rates of electron flow from many NADH and FADH₂ producing mitochondrial substrates, (2) Sensitivity of electron flow to a) 22 diverse mitochondrial inhibitors using different mitochondrial substrates, b) novel drugs or chemicals, c) mutations in genes that alter mitochondrial function.

Mitochondrial Electron Flow Assay Options



II. Product Descriptions

- **Products:** MitoPlates are 96-well microplates pre-coated with different tests which are dried on the bottom of each well. Other components of the assay are (1) A solution of the permeabilizing agent which must be prepared by the user, (2) The Biolog MAS solution which is osmotically optimized to preserve the physical structure of the cells following permeabilization, (3) The Biolog Redox Dye Mix which is used to measure the electron flow to the distal end of the electron transport chain, (4) A solution of the mitochondrial substrate which also must be prepared by the user. This solution is required only for the MitoPlate I-1.
- **Intended Use:** For Laboratory Use Only, to study the functional properties of mitochondria from permeabilized mammalian or other animal cells.
- **Product Storage:** MitoPlates should be refrigerated and stored at 4°C. Recommended storage conditions for chemical solutions are provided on their labels or should be determined by the user. MitoPlates may be taken out and prewarmed before use. For best results, use all products before the expiration date printed on the label.
- **Chemical Safety:** Safety Data Sheets for all products are available from Biolog and posted on the Biolog website at <http://biolog.com/msds/>.

III. Protocol Information

The protocol for MitoPlate S-1, the mitochondrial substrate plate, is provided on pages 5-6.

The protocol for MitoPlate I-1, the mitochondrial inhibitor plate, is provided on pages 7-9.

Preparation of Cells or Mitochondria

a. Cell Permeabilization

Whole cell assays require the use of permeabilizing agents that remove and sequester cholesterol from cell membranes. They work within seconds, allowing mitochondrial substrates and inhibitors to gain access to the mitochondria. We typically recommend a purified form of saponin, catalog number SAE0073 from Sigma-Aldrich. The effective range seems to be 12.5 to 100ug/ml, and generally speaking, 30 to 50ug/ml of saponin should be close to an optimal concentration for most cell types. Insufficient levels of saponin will give weak and partial permeabilization whereas excessive levels will damage the mitochondrial membrane, causing loss of mitochondria-associated electron flow and loss of sensitivity to mitochondrial inhibitors. Other permeabilizing agents may be substituted for saponin, for example digitonin or cholesterol-sequestering toxins, but these should be validated before use.

b. Mitochondria Purification

When it is not possible to use permeabilization, for example to assay mitochondria from tissue samples, mitochondria can be purified and assayed directly. Most purification methods require centrifugation, but a newer method gives excellent purification using filtration instead of centrifugation (J.M. Preble et al., (2014) J. Vis. Exp. (91) e51682).

c. Optimizing the Cell or Mitochondrial Concentration

30,000 cells per well or 50ug of mitochondrial protein per well is a good starting concentration. This may be adjusted up or down if the rate of color formation is too weak or too strong.

IV. MitoPlate S-1 Instructions For Use

MitoPlate S-1: Mitochondrial Function Assays Testing Substrates

A1 No Substrate	A2 α -D-Glucose	A3 Glycogen	A4 D-Glucose-1-PO4	A5 No Substrate	A6 α -D-Glucose	A7 Glycogen	A8 D-Glucose-1-PO4	A9 No Substrate	A10 α -D-Glucose	A11 Glycogen	A12 D-Glucose-1-PO4
B1 D-Glucose-6-PO4	B2 D-Gluconate-6-PO4	B3 D,L- α -Glycerol-PO4	B4 L-Lactic Acid	B5 D-Glucose-6-PO4	B6 D-Gluconate-6-PO4	B7 D,L- α -Glycerol-PO4	B8 L-Lactic Acid	B9 D-Glucose-6-PO4	B10 D-Gluconate-6-PO4	B11 D,L- α -Glycerol-PO4	B12 L-Lactic Acid
C1 Pyruvic Acid	C2 Citric Acid	C3 D,L-Isocitric Acid	C4 cis-Aconitic Acid	C5 Pyruvic Acid	C6 Citric Acid	C7 D,L-Isocitric Acid	C8 cis-Aconitic Acid	C9 Pyruvic Acid	C10 Citric Acid	C11 D,L-Isocitric Acid	C12 cis-Aconitic Acid
D1 α -Keto-Glutaric Acid	D2 Succinic Acid	D3 Fumaric Acid	D4 L-Malic Acid	D5 α -Keto-Glutaric Acid	D6 Succinic Acid	D7 Fumaric Acid	D8 L-Malic Acid	D9 α -Keto-Glutaric Acid	D10 Succinic Acid	D11 Fumaric Acid	D12 L-Malic Acid
E1 α -Keto-Butyric Acid	E2 D,L- β -Hydroxy-Butyric Acid	E3 L-Glutamic Acid	E4 L-Glutamine	E5 α -Keto-Butyric Acid	E6 D,L- β -Hydroxy-Butyric Acid	E7 L-Glutamic Acid	E8 L-Glutamine	E9 α -Keto-Butyric Acid	E10 D,L- β -Hydroxy-Butyric Acid	E11 L-Glutamic Acid	E12 L-Glutamine
F1 Ala-Gln	F2 L-Serine	F3 L-Ornithine	F4 Tryptamine	F5 Ala-Gln	F6 L-Serine	F7 L-Ornithine	F8 Tryptamine	F9 Ala-Gln	F10 L-Serine	F11 L-Ornithine	F12 Tryptamine
G1 L-Malic Acid 100uM	G2 Acetyl-L-Carnitine + L-Malic Acid 100uM	G3 Octanoyl-L-Carnitine + L-Malic Acid 100uM	G4 Palmitoyl-D,L-Carnitine + L-Malic Acid 100uM	G5 L-Malic Acid 100uM	G6 Acetyl-L-Carnitine + L-Malic Acid 100uM	G7 Octanoyl-L-Carnitine + L-Malic Acid 100uM	G8 Palmitoyl-D,L-Carnitine + L-Malic Acid 100uM	G9 L-Malic Acid 100uM	G10 Acetyl-L-Carnitine + L-Malic Acid 100uM	G11 Octanoyl-L-Carnitine + L-Malic Acid 100uM	G12 Palmitoyl-D,L-Carnitine + L-Malic Acid 100uM
H1 Pyruvic Acid + L-Malic Acid 100uM	H2 γ -Amino-Butyric Acid + L-Malic Acid 100uM	H3 α -Keto-Isocaproic Acid + L-Malic Acid 100uM	H4 L-Leucine + L-Malic Acid 100uM	H5 Pyruvic Acid + L-Malic Acid 100uM	H6 γ -Amino-Butyric Acid + L-Malic Acid 100uM	H7 α -Keto-Isocaproic Acid + L-Malic Acid 100uM	H8 L-Leucine + L-Malic Acid 100uM	H9 Pyruvic Acid + L-Malic Acid 100uM	H10 γ -Amino-Butyric Acid + L-Malic Acid 100uM	H11 α -Keto-Isocaproic Acid + L-Malic Acid 100uM	H12 L-Leucine + L-Malic Acid 100uM

Intended Use: To assay the function of mitochondria from cells using mitochondrial substrates as probes.

MitoPlate Layout: The MitoPlate has a triplicate repeat of a set of 30 substrates (rows A-B cytoplasmic, rows C-H mitochondrial) precoated and dried into the wells. Either 3 assay samples can be run or one sample in triplicate. The mitochondrial substrates are transported via different transporters and metabolized using different dehydrogenases and electron transport chain components. The MitoPlate can also be used to assess the specificity of substrate transport inhibitors, dehydrogenase inhibitors, or electron transport chain inhibitors.

Assay Principle: Mitochondrial function can be assayed by measuring the rates of electron flow into and through the electron transport chain from metabolic substrates that produce NADH (e.g. L-malate, α -ketoglutarate, D-isocitrate, L-glutamate, D- β -hydroxy-butyrate) or FADH₂ (e.g. succinate, α -glycerol-PO4). Each substrate follows a different route using different transporters to enter the mitochondria, and then different dehydrogenases to produce NADH or FADH₂. The electrons travel from the beginning (complex 1 or 2) to the distal portion of the electron transport chain where a tetrazolium redox dye (MC) acts as a terminal electron acceptor that turns purple upon reduction.

Recommended Protocol:

Prepare in advance 2x Biolog MAS (Mitochondrial Assay Solution, Biolog cat# 72303)
 6x Redox Dye MC (Biolog cat# 74353)
 24x Saponin (e.g. 720ug/ml for 30ug/ml; 1200ug/ml for 50ug/ml; see III.a.)
 Sterile water

<u>Assay Mix:</u>		<u>Volumes</u> <u>per well</u>	<u>Volumes</u> <u>per plate</u>	<u>1.4x extra</u> <u>for pipetting</u>
Combine	2x Biolog MAS	15ul	1500ul	2100ul
	6x Redox Dye MC	10ul	1000ul	1400ul
	24x Saponin	2.5ul	250ul	350ul
	<u>Sterile water</u>	<u>2.5ul</u>	<u>250ul</u>	<u>350ul</u>
Add to wells	TOTAL	30ul	3000ul	4200ul

Cell Suspension Preparation – 2x cells in 1x Biolog MAS

Harvest and resuspend cells in 1x Biolog MAS. Filter the cell suspension through a 70 micron nylon filter (cell strainer, Falcon 352350) to remove clumps. Count the cell number and determine their viability with trypan blue. The cells should have viability >95%.

Typical cell lines: For a final cell density of 30,000 cells per well, one plate requires a total of 3×10^6 cells in 3 ml of 1x Biolog MAS (1,000,000 cells per ml).

Typical blood cells: For a final cell density of 120,000 cells per well, one plate requires a total of 12×10^6 cells in 3 ml of 1x Biolog MAS (4,000,000 cells per ml).

Typical purified mitochondria: For a final concentration of 50ug of protein per well, one plate requires a total of 5mg of mitochondrial protein in 3 ml of 1x Biolog MAS. Saponin is not used and is replaced by sterile water.

Assay Steps:

1. Pipet 30ul per well of the Assay Mix into all wells and incubate at 37° C for 1 hour to allow substrates to fully dissolve.
2. Dispense the Cell Suspension to all wells by adding 30ul per well of the 2x cell suspension in 1x Biolog MAS.
3. Load the MitoPlate into the OmniLog® for kinetic reading of the rate of purple color formation. Alternatively, the color formation can be read kinetically on a microplate reader using OD₅₉₀.

Ordering Information:

<u>Catalog #</u>	<u>Description</u>
14105	MitoPlate S-1
72303	Biolog MAS
74353	Biolog Redox Dye Mix MC
96161	OmniLog PM-M System (NA Plug)
96162	OmniLog PM-M System (Schuko Plug)
96164	OmniLog PM-M System (UK Plug)
Not Included:	Saponin permeabilizing solution

V. MitoPlate I-1 Instructions For Use

MitoPlate I-1: Mitochondrial Function Assays Testing Inhibitors

A1 No inhibitor No substrate With Saponin	A2 No inhibitor No substrate With Saponin	A3 No inhibitor No substrate With Saponin	A4 No inhibitor No substrate With Saponin	A5 No inhibitor With substrate With Saponin	A6 No inhibitor With substrate With Saponin	A7 No inhibitor With substrate With Saponin	A8 No inhibitor With substrate With Saponin	A9 Meclizine	A10	A11	A12
1								1	2	3	4
B1 Complex I Inhibitor Rotenone	B2	B3	B4	B5 Complex I Inhibitor Pyridaben	B6	B7	B8	B9 Berberine	B10	B11	B12
1	2	3	4	1	2	3	4	1	2	3	4
C1 Complex II Inhibitor Malonate	C2	C3	C4	C5 Complex II Inhibitor Carboxin	C6	C7	C8	C9 Alexidine	C10	C11	C12
1	2	3	4	1	2	3	4	1	2	3	4
D1 Complex III Inhibitor Antimycin A	D2	D3	D4	D5 Complex III Inhibitor Myxothiazol	D6	D7	D8	D9 Phenformin	D10	D11	D12
1	2	3	4	1	2	3	4	1	2	3	4
E1 Uncoupler FCCP	E2	E3	E4	E5 Uncoupler 2,4-Dinitrophenol	E6	E7	E8	E9 Diclofenac	E10	E11	E12
1	2	3	4	1	2	3	4	1	2	3	4
F1 Ionophore, K Valinomycin	F2	F3	F4	F5 Calcium CaCl ₂	F6	F7	F8	F9 Celestrol	F10	F11	F12
1	2	3	4	1	2	3	4	1	2	3	4
G1 Gossypol	G2	G3	G4	G5 Nordihydro- guaiaretic acid	G6	G7	G8	G9 Trifluoperazine	G10	G11	G12
1	2	3	4	1	2	3	4	1	2	3	4
H1 Polymyxin B	H2	H3	H4	H5 Amitriptyline	H6	H7	H8	H9 Papaverine	H10	H11	H12
1	2	3	4	1	2	3	4	1	2	3	4

Intended Use: To assay the function of mitochondria from cells using mitochondrial inhibitors as probes.

MitoPlate Layout: The MitoPlate has 22 mitochondrial inhibitors at 4 dilutions precoated and dried into the wells. There are also 2 sets of control wells, each well repeated 4 times (negative control A1-A4 and positive control A5-A8).

Assay Principle: Mitochondrial function can be assayed by measuring the sensitivity of mitochondria to this set of 22 diverse inhibitors. The assays can be run with different metabolic substrates that produce NADH (e.g. L-malate, α -ketoglutarate, D-isocitrate, L-glutamate, D- β -hydroxy-butyrate) or FADH₂ (e.g. succinate, α -glycerol-PO₄). Each substrate feeds electrons into the electron transport chain following a different route. The electrons travel from the beginning (complex 1 or 2) to the distal portion of the electron transport chain where a tetrazolium redox dye (MC) acts as a terminal electron acceptor that turns purple upon reduction. For example, a metabolic substrate that feeds complex 1 (L-malate) will result in a strong flow of electrons via malate dehydrogenase, which can be inhibited by either a complex 1 inhibitor (rotenone, pyridaben) or a complex 3 inhibitor (antimycin A, myxothiazol). A metabolic substrate that feeds complex 2 (succinate) will result in a strong flow of electrons via succinate dehydrogenase, which can be inhibited by either a complex 2 inhibitor (malonate, carboxin) or a complex 3 inhibitor (antimycin A, myxothiazol). The Reference section provides some references on the mode of action of the 22 inhibitors.

Recommended Protocol:

Prepare in advance: 2x Biolog MAS (Mitochondrial Assay Solution, Biolog cat# 72303)
6x Redox Dye MC, (Biolog cat# 74353)
24x Saponin (e.g. 720ug/ml for 30ug/ml; 1200ug/ml for 50ug/ml; see III.a.)
24x Substrate (e.g. 96mM sodium L-malate or succinate, pH7.2)
Sterile water

<u>Assay Mix with Substrate:</u>		Volumes <u>per well</u>	Volumes <u>per plate</u>	1.4x extra <u>for pipetting</u>
Combine	2x Biolog MAS	15ul	1500ul	2100ul
	6x Redox Dye MC	10ul	1000ul	1400ul
	24x Saponin	2.5ul	250ul	350ul
	24x Substrate	2.5ul	250ul	350ul
Add to wells	TOTAL	30ul	3000ul	4200ul

For negative control wells A1-A4

<u>Assay Mix with No Substrate:</u>		Volumes <u>per well</u>	Volumes <u>per plate</u>	4x extra <u>for pipetting*</u>
Combine	2x Biolog MAS	15ul	60ul	240ul
	6x Redox Dye MC	10ul	40ul	160ul
	24x Saponin	2.5ul	10ul	40ul
	Sterile water	2.5ul	10ul	40ul
Add to wells	TOTAL	30ul	120ul	480ul

* If using a multi-channel pipettor and a reagent reservoir, you will need 4x reagent volume to fill tips accurately. If you prefer to use a single-channel pipet for wells A1 – A4, you may use 1.4x volume.

Cell Suspension Preparation – 2x cells in 1x Biolog MAS

Harvest and resuspend cells in 1x Biolog MAS. Filter the cell suspension through a 70 micron nylon filter (cell strainer, Falcon 352350) to remove clumps. Count the cell number and determine their viability with trypan blue. The cells should have viability >95%.

Typical cell lines: For a final cell density of 30,000 cells per well, one plate requires a total of 3×10^6 cells in 3 ml of 1x Biolog MAS (1,000,000 cells per ml).

Typical blood cells: For a final cell density of 120,000 cells per well, one plate requires a total of 12×10^6 cells in 3 ml of 1x Biolog MAS (4,000,000 cells per ml).

Typical purified mitochondria: For a final concentration of 50ug of protein per well, one plate requires a total of 5mg of mitochondrial protein in 3 ml of 1x Biolog MAS. Saponin is not used and is replaced by sterile water.

Assay Steps:

1. Pipet 30ul per well of the Assay Mix with No Substrate into the negative control wells, A1-A4.
2. Pipet 30ul per well of the Assay Mix with Substrate into all other wells. Start with Column 12 and pipet from Column 12 to Column 5 using eight pipet tips. Then detach one pipet tip and fill wells B4-H4, B3-H3, B2-H2, and B1-H1.
3. Dispense the Cell Suspension to all wells by adding 30ul per well of the 2x cell suspension in 1x Biolog MAS.
4. Load the MitoPlate into the OmniLog® for kinetic reading of the rate of purple color formation. Alternatively, the color formation can be read kinetically on a microplate reader using OD₅₉₀.

Ordering Information:

Catalog #	Description
14104	MitoPlate I-1
72303	Biolog MAS
74353	Biolog Redox Dye Mix MC
96161	OmniLog PM-M System (NA Plug)
96162	OmniLog PM-M System (Schuko Plug)
96164	OmniLog PM-M System (UK Plug)

Not Included: Saponin permeabilizing solution and substrate solutions for MitoPlate I-1

VI. References

Meclizine

1. Meclizine inhibits mitochondrial respiration through direct targeting of cytosolic phosphoethanolamine metabolism. Vishal M. Gohil, Lin Zhu, Charli D. Baker, Valentin Cracan, Abbas Yaseen, Mohit Jain, Clary B. Clish, Paul S. Brookes, Marica Bakovic, and Vamsi K. Mootha. *J Biol Chem.* 2013; 288(49):35387–35395.

Rotenone

2. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. Li N1, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, Robinson JP. *J Biol Chem.* 2003; 278(10):8516–8525.

Pyridaben

3. Effects of rotenone and pyridaben on complex I electron transfer and on mitochondrial nitric oxide synthase functional activity. Navarro A, Bández MJ, Gómez C, Repetto MG, Boveris A.. *J Bioenerg Biomembr.* 2010; 42(5):405-12.

Berberine

4. Mechanisms of berberine (Natural Yellow 18)–induced mitochondrial dysfunction: Interaction with the adenine nucleotide translocator. Claudia V. Pereira, Nuno G. Machado, and Paulo J. Oliveira. *Toxicol Sci.* 2008; 105(2):408–417.
5. Mitochondria and NMDA Receptor-Dependent Toxicity of Berberine Sensitizes Neurons to Glutamate and Rotenone Injury. Kysenius K, Brunello CA, Huttunen HJ. *PLoS ONE.* 2014; 9(9): e107129.

Malonate

6. Succinate dehydrogenase inhibition with malonate during reperfusion reduces infarct size by preventing mitochondrial permeability transition. Valls-Lacalle L, Barba I, Miró-Casas E, Alburquerque-Béjar JJ, Ruiz-Meana M, Fuertes-Agudo M, Rodríguez-Sinovas A, García-Dorado D. *Cardiovasc Res.* 2016 Mar 1;109(3):374-84.
7. Mitochondrial complex II can generate reactive oxygen species at high rates in both the forward and reverse reactions. Quinlan CL, Orr AL, Perevoshchikova IV, Treberg JR, Ackrell BA, Brand MD. *J Biol Chem.* 2012 Aug 3;287(32):27255-64.
8. Substrate-Specific Reduction of Tetrazolium Salts by Isolated Mitochondria, Tissues, and Leukocytes. Fedotcheva NI, Litvinova EG, Zakharchenko MV, Khunderyakova NV, Fadeev RS, Teplova VV, Fedotcheva TA, Beloborodova NV, Kondrashova MN. *Biochemistry (Mosc).* 2017 Feb;82(2):192-204

Carboxin

9. Studies on the binding of carboxin analogs to succinate dehydrogenase. Christopher J. Coles, Thomas P. Singer, Gordon A. White, and G. Denis Thorn. *J Biol Chem.* 1978; 253(16):5573-5578.

Alexidine

10. Pharmacological targeting of the mitochondrial phosphatase PTPMT1. Doughty-Shenton D1, Joseph JD, Zhang J, Pagliarini DJ, Kim Y, Lu D, Dixon JE, Casey PJ. *J Pharmacol Exp Ther.* 2010; 333(2):584-92.
11. PTPMT1 inhibition lowers glucose through succinate dehydrogenase phosphorylation. Nath AK, Ryu JH, Jin YN, Roberts LD, Dejam A, Gerszten RE, Peterson RT. *Cell Reports.* 2015; 10(5):694–701.

Antimycin A and Myxothiazol

12. Mitochondrial Electron Transport Chain Complex III Is Required for Antimycin A to Inhibit Autophagy. Xiuquan

Ma, Mingzhi Jin, Yu Cai, Hongguang Xia, Kai Long, Junli Liu, Qiang Yu and Junying Yuan. *Chem Biol.* 2011; 18(11):1474–1481.

Phenformin

13. Targeting mitochondria metabolism for cancer therapy. Samuel E Weinberg and Navdeep S Chandel. *Nat Chem Biol.* 2015; 11(1): 9–15.
14. Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase. Hannah R. Bridges, Ville A. Sirviö, Ahmed-Noor A. Agip, and Judy Hirst. *BMC Biol.* 2016; 14: 65.

FCCP

15. Mitochondrial uncoupler FCCP activates proton conductance but does not block store-operated Ca(2+) current in liver cells. To MS, Aromataris EC, Castro J, Roberts ML, Barritt GJ, Rychkov GY. *Arch Biochem Biophys.* 2010; 495(2):152-8.

2,4-Dinitrophenol

16. Dinitrophenol-induced mitochondrial uncoupling in vivo triggers respiratory adaptation in HepG2 cells. Valérie Desquret, Dominique Loiseau, Caroline Jacques, Olivier Douay, Yves Malthiery, Patrick Ritz, Damien Roussel. *Biochimica et Biophysica Acta.* 2006; 1757(1):21–30.

Diclofenac

17. Mitochondrial toxicity of diclofenac and its metabolites via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria: Possible role in drug induced liver injury (DILI). Syed M, Skonberg C, Hansen SH. *Toxicol In Vitro.* 2016; 31:93-102.
18. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Schmeltzer PA1, Kosinski AS2, Kleiner DE3, Hoofnagle JH3, Stolz A4, Fontana RJ5, Russo MW1; Drug-Induced Liver Injury Network (DILIN). *Liver Int.* 2016;36(4):603-9.
19. Action of diclofenac on kidney mitochondria and cells. Ng LE1, Vincent AS, Halliwell B, Wong KP. *Biochem Biophys Res Commun.* 2006; 348(2):494-500.
20. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Masubuchi Y1, Nakayama S, Horie T. *Hepatology.* 2002; 35(3):544-51.

Valinomycin

21. Relationship of potassium ion transport and ATP synthesis in pea cotyledon mitochondria. Hamman WM, Spencer M. *Can J Biochem.* 1977; 55(4):376-83.
22. Valinomycin can depolarize mitochondria in intact lymphocytes without increasing plasma membrane potassium fluxes. Suzanne M. Felber and Martin D. Brand. *FEBS Letters.* 1982; 150(1):122-124.
23. Valinomycin induced energy-dependent mitochondrial swelling, cytochrome c release, cytosolic NADH/cytochrome c oxidation and apoptosis. Lofrumento DD1, La Piana G, Abbrescia DI, Palmitessa V, La Pesa V, Marzulli D, Lofrumento NE. *Apoptosis.* 2011; 16(10):1004-13.

Calcium

24. Mitochondrial calcium and the permeability transition in cell death. John J. Lemasters, Tom P. Theruvath, Zhi Zhong, Anna-Liisa Nieminen. *Biochimica et Biophysica Acta.* 2009; 1787 (11):1395–1401.
25. Calcium and apoptosis: ER-mitochondria Ca²⁺ transfer in the control of apoptosis. P Pinton, C Giorgi, R Siviero, E Zecchini and R Rizzut. *Oncogene.* 2008; 27(50):6407–6418.
26. Mitochondrial calcium overload is a key determinant in heart failure. Gaetano Santullia, Wenjun Xiea, Steven R. Reikena, and Andrew R. Marks. *Proc Natl Acad Sci USA.* 2015; 112(36):11389–11394.

Celastrol

27. Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells. Guozhu Chen, Xuhui Zhang, Ming Zhao, Yan Wang, Xiang Cheng, Di Wang, Yuanji Xu, Zhiyan Du and Xiaodan Yu. Chen et al. *BMC Cancer.* 2011; 11:170.
28. Celastrol induces mitochondria-mediated apoptosis in hepatocellular carcinoma Bel-7402 cells. Pei-Pei Li., Wei He, Ping-Fan Yuan, Sha-Sha Song, Jing-Tao Lu and Wei We. *Am. J. Chin. Med.* 2015; 43:137-148.

Gossypol

29. Gossypol inhibits electron transport and stimulates ROS generation in *Yarrowia lipolytica* mitochondria. Anna Yu Arinbasarova, Alexander G Medentsev, and Vladimir I Krupyanko. *Open Biochem J.* 2012; 6:11–15.
30. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Oliver CL, Miranda MB, Shangary S, Land S, Wang S, Johnson DE. *Mol Cancer Ther.* 2005; 4(1):23-31.

Nordihydroguaiaretic Acid

31. Glutathione Oxidation and Mitochondrial Depolarization as Mechanisms of Nordihydroguaiaretic Acid-Induced Apoptosis in Lipoxygenase-Deficient FL5.12 Cells. Shyam S. Biswal, Kaushik Datta, Stephanie D. Shaw, Xiang Feng, John D. Robertson, and James P. Kehrer. *Toxicological Sciences.* 2000; 53, 77–83.
32. Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: An update. Jian-Ming Lü, Jacobo Nurko, Sarah M. Weakley, Jun Jiang, Panagiotis Kougiaris, Peter H. Lin, Qizhi Yao, and Changyi Chen. *Med Sci Monit.* 2010 April 28; 16(5): RA93–R100.
33. Paradoxical cellular effects and biological role of the multifaceted compound nordihydroguaiaretic acid. Hernández-Damián JI, Andérica-Romero AC, Pedraza-Chaverri J. *Arch Pharm (Weinheim).* 2014 Oct;347(10):685-97.

Trifluoperazine

34. Cytotoxicity of phenothiazine derivatives associated with mitochondrial dysfunction: a structure-activity investigation. de Faria PA, Bettanin F, Cunha RL, Paredes-Gamero EJ, Homem-de-Mello P, Nantes IL, and Rodrigues T. *Toxicology.* 2015 Apr 1;330:44-54.
35. Effect of trifluoperazine on toxicity, HIF-1 α induction and hepatocyte regeneration in acetaminophen toxicity in mice. Chaudhuri S, McCullough SS, Hennings L, Brown AT, Li SH, Simpson PM, Hinson JA, James LP. *Toxicol Appl Pharmacol.* 2012 Oct 15;264(2):192-201.
36. Inhibition of MPP⁺-induced mitochondrial damage and cell death by trifluoperazine and W-7 in PC12 cells. Lee CS1, Park SY, Ko HH, Song JH, Shin YK, Han ES. *Neurochem Int.* 2005 Jan;46(2):169-78.

Polymyxin B

37. Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells. Mohammad A. K. Azad, Jesmin Akter, Kelly L. Rogers, Roger L. Nation, Tony Velkov and Jian Li. *Antimicrob. Agents Chemother.* 2015; 59(4):2136-2143.
38. Polymyxin B nephrotoxicity: From organ to cell damage. Vattimo MdFF, Watanabe M, da Fonseca CD, Neiva LBdM, Pessoa EA, Borges FT. *PLoS One.* 2016; 11(8):e0161057.
39. Polymyxin B identified as an Inhibitor of alternative NADH Dehydrogenase and Malate: Quinone Oxidoreductase from the Gram-positive bacterium *Mycobacterium smegmatis*. Tatsushi Mogi Yoshiro Murase Mihoko Mori Kazuro Shiomi Satoshi Omura Madhavi P. Paranagama Kiyoshi Kita. *J Biochem.* 2009; 146(4):491-499.

Amitriptyline

40. Amitriptyline induces mitophagy that precedes apoptosis in human HepG2 cells. Marina Villanueva-Paz, Mario D. Cordero, Ana Delgado Pavón et al. *Genes Cancer.* 2016; 7(7-8): 260–277.
41. Oral treatment with amitriptyline induces coenzyme Q deficiency and oxidative stress in psychiatric patients. Moreno-Fernández AM1, Cordero MD, Garrido-Maraver J, Alcocer-Gómez E, Casas-Barquero N, Carmona-López MI, Sánchez-Alcázar JA, de Miguel M. *J Psychiatr Res.* 2012; 46(3):341-5.

Papaverine

42. Effect of dopamine, dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial respiration and complex I activity. Nami Morikawa, Yuko Nakagawa-Hattori, Yoshikuni Mizuno. *J Neurochemistry.* 1996; 66(3):1174–1181.
43. Effect of papaverine on the energy processes of myocardial mitochondria. Urakov AL, Baranov AG. *Farmakol Toksikol.* 1979; 42(2):132-6.
44. Identification of small molecules that improve ATP synthesis defects conferred by Leber's hereditary optic neuropathy mutations. Sandipan Datta, Alexey Tomilov, Gino Cortopassi. *Mitochondrion.* 2016; 30:177–186.

VII. Frequently Asked Questions

What saponin product does Biolog recommend for permeabilization?

- From our experience, the best saponin product on the market that we have tested is Sigma Aldrich's saponin, product number SAE0073. It has the highest **sapogenin** content (20-35%) of any saponin product that we have tested, which we have correlated with having a broad window of efficacy.

What concentration of saponin do you recommend for my cell line?

- First we recommend that you run a preliminary test of your cell line in a MitoPlate S-1 using three concentrations of saponin and choosing the best concentration based on the highest signal from dye reduction. Of cells that we have tested, the optimal concentration has ranged between 10 and 100 µg/ml. Usually, the optimal concentration is about 50 µg/ml. Therefore we suggest testing 25-50-75 µg/ml or 30-50-70 µg/ml. However, it is always possible that the optimal concentration may be higher or lower for a specific type of cell or permeabilization may work better with digitonin instead of saponin.

My cells cannot be lifted and re-suspended. Can the assay still work for me?

- Yes, instead of adding the cell suspension to the MitoPlate, you can re-hydrate the 96 wells of the MitoPlate, and transfer the chemistry to another 96-well plate, containing the cells.

Can MitoPlates work for tissue samples?

- Yes, you can purify mitochondria from the tissue and use a mitochondrial suspension to inoculate the wells according to the protocol, leaving out the saponin permeabilization. When using this method, we recommend to standardize across tests by protein concentration, using approximately 50 to 100 µg of mitochondrial protein per well. Any good method of mitochondrial purification can be used, as long as organelle structure is maintained.

Why does it say that the cell suspension is at 2x?

- Because the cell suspension is added at 30 µl volumes to a well that already contains 30 µl of assay mix – the cell suspension becomes 1x once added to the well.

What volume does each plate require of each reagent?

- As described in the Instructions for Use (IFU) on page 6, calculations of final volumes are based on adding an extra 40% of each volume to provide some excess to allow for easier pipetting. With this in mind, use about 4.6 ml of Biolog MAS Buffer (this includes the volume needed for the cell suspension), and 1.4 ml of Dye Mix MC per plate.

How do I read the MitoPlates?

- The best option is to use an OmniLog® PM-M System which is a multiplate kinetic reader with temperature control. In addition, the plates can also be read on a microplate reader. In this case, we recommend to read OD at both 590 nm and 750 nm, and then subtract signal at 750 nm from 590 nm, at every read point. This is to minimize any abiotic background. A typical assay should run for 2 to 6 hours with 5 minute read intervals, if possible.

Should the MitoPlates be read with the lid on or lid off?

- Fogging of the lid or scratches and other non-uniformities will scatter the light beam and cause false readings. Therefore the lids should be removed when reading the plates.

At what temperature should I read the MitoPlates?

- Plates should be kept at 35-37° C if possible for mammalian cells.

How do I analyze the data from reading MitoPlates?

- In our experience, the best data is the initial linear slope rate in the first 2 hours.

How can I increase the signal & reproducibility, and decrease the background & noise?

- The signal can be increased by optimizing the saponin concentration and/or adding more cells per well. Reproducibility is obtained by careful and gentle handling and pipetting of all solutions, especially the cell suspension. A common source of background and noise is the formation of bubbles which can occur due to foaming by the saponin and by too rapid filling and dispensing with the pipetter. Better results can be obtained by slow and careful filling and dispensing. Bubbles will cause light scattering and noise when measuring absorbance in a microplate reader.